Argenx Se (1AEA) Stock Forecast & Price Target

19 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1AEA Analyst Ratings

Strong Buy

20 Buy

1 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Argenx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1AEA Stock 12 Month Forecast

Average Price Target

€1,040.33

▲(19.58% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Argenx Se in the last 3 months. The average price target is €1,040.33 with a high forecast of €1,244.79 and a low forecast of €819.89. The average price target represents a 19.58% change from the last price of €870.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"599":"€599","922":"€922","1245":"€1,245","760.5":"€760.5","1083.5":"€1,083.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1244.78991885,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.24K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1040.326750479474,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.04K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":819.88989708,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€819.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[599,760.5,922,1083.5,1245],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,895,921.9069168346153,948.8138336692308,975.7207505038461,1002.6276673384616,1029.5345841730768,1056.4415010076923,1083.3484178423078,1110.2553346769232,1137.1622515115384,1164.069168346154,1190.9760851807691,1217.8830020153846,{"y":1244.78991885,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,895,906.1789808061134,917.3579616122267,928.5369424183401,939.7159232244535,950.8949040305669,962.0738848366802,973.2528656427937,984.4318464489071,995.6108272550205,1006.7898080611338,1017.9687888672472,1029.1477696733605,{"y":1040.326750479474,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,895,889.2222997753846,883.4445995507692,877.6668993261538,871.8891991015385,866.1114988769231,860.3337986523077,854.5560984276923,848.7783982030769,843.0006979784615,837.2229977538461,831.4452975292307,825.6675973046154,{"y":819.88989708,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":600,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":615,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":705,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":770,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":700,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":690,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":640,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":625,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":655,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":710,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":800,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":750,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":895,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€1,245

Average Price Target€1,040

Lowest Price Target€819.89

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

09/29/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Argenx Se (NASDAQ: ARGX) and Obsidian Therapeutics (NASDAQ: OBX)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€1,068.85

Buy

22.86%

Upside

Reiterated

09/15/26

Jefferies Sticks to Its Buy Rating for Argenx Se (ARGX)

David Nierengarten

Wedbush

€1,011.67

Buy

16.28%

Upside

Reiterated

09/03/26

Analysts' Top Healthcare Picks: Argenx Se (ARGX), TELA Bio (TELA)

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Definitive Healthcare Corp (NASDAQ: DH)

Sean Laaman

Morgan Stanley

€1,099.64

Buy

26.40%

Upside

Assigned

09/01/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Ascendis Pharma (ASND)

Derek Archila

Wells Fargo

€1,187.61→€1,244.79

Buy

43.08%

Upside

Assigned

08/26/26

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (NYSE: SOLV), Argenx Se (NASDAQ: ARGX) and Spyre Therapeutics (NASDAQ: SYRE)

Xian Deng

UBS

€844.52→€1,231.59

Buy

41.56%

Upside

Upgraded

08/26/26

UBS upgrades Argenx Se (ARGX) to a Buy

Douglas Tsao

H.C. Wainwright

€1,057.41

Buy

21.54%

Upside

Reiterated

08/24/26

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

Jason Butler

Citizens JMP

€819.89→€1,055.65

Buy

21.34%

Upside

Reiterated

08/18/26

Argenx price target raised to $1,200 from $932 at CitizensArgenx price target raised to $1,200 from $932 at Citizens

Danielle Brill

Truist Financial

€906.1→€963.28

Buy

10.72%

Upside

Reiterated

08/18/26

Argenx price target raised to $1,095 from $1,030 at TruistArgenx price target raised to $1,095 from $1,030 at Truist

Leland Gershell

Oppenheimer

€912.26→€967.68

Buy

11.23%

Upside

Reiterated

08/18/26

Argenx price target raised to $1,100 from $1,037 at OppenheimerArgenx price target raised to $1,100 from $1,037 at Oppenheimer

Samantha Semenkow

Citi

€1,058.29→€1,144.5

Buy

31.55%

Upside

Reiterated

08/18/26

Argenx Se (ARGX) Receives a Buy from Citi

Yaron Werber

TD Cowen

€1,008.15→€1,190.25

Buy

36.81%

Upside

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Amgen (NASDAQ: AMGN)

Allison Bratzel

Piper Sandler

€945.69→€1,068.85

Buy

22.86%

Upside

Reiterated

08/17/26

Argenx price target raised to $1,215 from $1,075 at Piper SandlerArgenx price target raised to $1,215 from $1,075 at Piper Sandler

Luca Issi

RBC Capital

€901.7→€967.68

Buy

11.23%

Upside

Reiterated

08/17/26

Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Tenon Medical, Inc. (TNON)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

09/29/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Argenx Se (NASDAQ: ARGX) and Obsidian Therapeutics (NASDAQ: OBX)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€1,068.85

Buy

22.86%

Upside

Reiterated

09/15/26

Jefferies Sticks to Its Buy Rating for Argenx Se (ARGX)

David Nierengarten

Wedbush

€1,011.67

Buy

16.28%

Upside

Reiterated

09/03/26

Analysts' Top Healthcare Picks: Argenx Se (ARGX), TELA Bio (TELA)

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Definitive Healthcare Corp (NASDAQ: DH)

Sean Laaman

Morgan Stanley

€1,099.64

Buy

26.40%

Upside

Assigned

09/01/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Ascendis Pharma (ASND)

Derek Archila

Wells Fargo

€1,187.61→€1,244.79

Buy

43.08%

Upside

Assigned

08/26/26

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (NYSE: SOLV), Argenx Se (NASDAQ: ARGX) and Spyre Therapeutics (NASDAQ: SYRE)

Xian Deng

UBS

€844.52→€1,231.59

Buy

41.56%

Upside

Upgraded

08/26/26

UBS upgrades Argenx Se (ARGX) to a Buy

Douglas Tsao

H.C. Wainwright

€1,057.41

Buy

21.54%

Upside

Reiterated

08/24/26

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

Jason Butler

Citizens JMP

€819.89→€1,055.65

Buy

21.34%

Upside

Reiterated

08/18/26

Argenx price target raised to $1,200 from $932 at CitizensArgenx price target raised to $1,200 from $932 at Citizens

Danielle Brill

Truist Financial

€906.1→€963.28

Buy

10.72%

Upside

Reiterated

08/18/26

Argenx price target raised to $1,095 from $1,030 at TruistArgenx price target raised to $1,095 from $1,030 at Truist

Leland Gershell

Oppenheimer

€912.26→€967.68

Buy

11.23%

Upside

Reiterated

08/18/26

Argenx price target raised to $1,100 from $1,037 at OppenheimerArgenx price target raised to $1,100 from $1,037 at Oppenheimer

Samantha Semenkow

Citi

€1,058.29→€1,144.5

Buy

31.55%

Upside

Reiterated

08/18/26

Argenx Se (ARGX) Receives a Buy from Citi

Yaron Werber

TD Cowen

€1,008.15→€1,190.25

Buy

36.81%

Upside

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Amgen (NASDAQ: AMGN)

Allison Bratzel

Piper Sandler

€945.69→€1,068.85

Buy

22.86%

Upside

Reiterated

08/17/26

Argenx price target raised to $1,215 from $1,075 at Piper SandlerArgenx price target raised to $1,215 from $1,075 at Piper Sandler

Luca Issi

RBC Capital

€901.7→€967.68

Buy

11.23%

Upside

Reiterated

08/17/26

Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Tenon Medical, Inc. (TNON)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ESTAEstablishment Labs Holdings

LGNDLigand Pharma

HROWHarrow Health

STOKStoke Therapeutics

AXGNAxoGen

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Argenx Se

3 Months

Yatin SunejaGuggenheim

Success Rate

17/21 ratings generated profit

Average Return

+7.59%

Copying Yatin Suneja's trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +7.59% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

26/27 ratings generated profit

Average Return

+32.22%

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 96.30% of your transactions generating a profit, with an average return of +32.22% per trade.

2 Years

Akash TewariJefferies

Success Rate

29/29 ratings generated profit

Average Return

+70.63%

Copying Akash Tewari's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +70.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1AEA Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1AEA has received 53 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 1AEA average Analyst price target in the past 3 months is 1,040.33.

Each month's total comprises the sum of three months' worth of ratings.

1AEA Financial Forecast

1AEA Earnings Forecast

Next quarter’s earnings estimate for 1AEA is €6.77 with a range of €5.63 to €8.35. The previous quarter’s EPS was €6.46. 1AEA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1AEA has Performed in-line its overall industry.

1AEA Sales Forecast

Next quarter’s sales forecast for 1AEA is €1.46B with a range of €1.35B to €1.51B. The previous quarter’s sales results were €2.48B. 1AEA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1AEA has Performed in-line its overall industry.

1AEA Stock Forecast FAQ

What is DE:1AEA’s average 12-month price target, according to analysts?

Based on analyst ratings, Argenx Se’s 12-month average price target is 1,040.33.

What is DE:1AEA’s upside potential, based on the analysts’ average price target?

Argenx Se has 19.58% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Argenx Se a Buy, Sell or Hold?

Argenx Se has a consensus rating of Strong Buy, which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.

What is Argenx Se’s share price target?

The average share price target for Argenx Se is 1,040.33. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1,244.79 ,and the lowest forecast is €819.89. The average share price target represents 19.58% Increase from the current price of €870.

What do analysts say about Argenx Se?

Argenx Se’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Argenx Se?

To buy shares of DE:1AEA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Argenx Se (1AEA) Stock Forecast & Price Target

1AEA Analyst Ratings

1AEA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Argenx Se

1AEA Analyst Recommendation Trends

1AEA Financial Forecast

1AEA Earnings Forecast

1AEA Sales Forecast

1AEA Stock Forecast FAQ

Detailed List of Analyst Forecasts